[{"orgOrder":0,"company":"Five Leaf Labs","sponsor":"Cannaworx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Phytocannabinoid","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Five Leaf Labs","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Leaf Labs \/ Cannaworx","highestDevelopmentStatusID":"15","companyTruncated":"Five Leaf Labs \/ Cannaworx"}]

Find Clinical Drug Pipeline Developments & Deals by Five Leaf Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : Cannaworx and its Principals twelve products for market launch in the coming year, including two novel products derived from the company's pain relief phytocannabinoid formulations. Acquisition of 5 leaf labs offers access to more than 50 sales members i...

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          May 19, 2020

                          Lead Product(s) : Phytocannabinoid

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Cannaworx

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank